Nibourel O, Guihard S, Roumier C, Pottier Letter, Terre C, Paquet arablounge free app Good, Peyrouze P, Geffroy S, Quentin S, Alberdi A great, Abdelali RB, Renneville An excellent, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-amount data known brand new prognostic ;31(3):555-564.
Mohamed Have always been, Balsat Yards, Koering C, Maucort-Boulch D, Boissel N, Payen-Homosexual L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri Yards, Tigaud I, Hayette S, Dumontet C, Cros Elizabeth, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet Meters, Ceraulo A, Mortreux F, Wattel Elizabeth. Leuk Res. 2017;-twenty-eight.
Mishima Y, Paiva B, Shi J, Playground J, Manier S, Takagi S, Massoud Meters, Perilla-Glen Good, Aljawai Y, Huynh D, Roccaro Am, Sacco Good, Capelletti Yards, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha Grams, Freeman SS, Van Allen EM, Adalsteinsson Va, Michor F, San Miguel JF, Ghobrial I will be. 2017;19(1):218-224.
Minnema MC, Kimby Age, DSa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A great, Simon L, Davi F, Lunn Meters, Castillo JJ, Patterson CJ, Ce Garff-Tavernier Meters, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Tip into the diagnosis, treatment and you may effect requirements to have Yahoo-Neel problem. Haematologica. 2017;102(1):43-51.
Micol JB, Pastore A, Inoue D, Duployez N, Kim Age, Lee South carolina, Durham BH, Chung Yr, Cho H, Zhang XJ, Yoshimi A beneficial, Krivtsov An effective, Koche R, Solary Age, Sinha A good, Preudhomme C, Abdel-Wahab O. ASXL2 is very important getting haematopoiesis and you will will act as a good haploinsufficient tumour suppressor when you look at the leukemia. Nat Commun. 2017;8:15429.
Cell Agent
Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet Meters, Wang Y, Faure P, Szymanski Grams, Duployez N, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Park S. Activated oxygen species membership control NF-kappaB activation by reasonable amount deferasirox during the erythroid progenitors out-of low exposure myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.
Manier S, Salem KZ, Playground J, Landau Weil, Getz G, Ghobrial Im. Genomic complexity of numerous myeloma and its scientific effects. Nat Rev Clin Oncol. 2017;14(2):100-113.
Manier S, Energies JT, Sacco A beneficial, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro In the morning, Daley GQ, Ghobrial Im. New LIN28B/let-eight axis are a manuscript therapeutic pathway into the several myeloma. Leukemia. 2017;31(4):853-860.
Manier S, Liu CJ, Avet-Loiseau H, Playground J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A good, Roccaro Are, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial Im. Prognostic role away from releasing exosomal miRNAs when you look at the several myeloma. Bloodstream. 2017;129(17):2429-2436.
TET2 exon dos skipping try a different positive prognostic factor to own cytogenetically typical acute myelogenous leukemia (AML): TET2 exon 2 missing in the AML
Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown Le, Grey Letter, Bradner J, Whitesell L, Porco JA, Jr., Ghobrial I will be. Inhibiting the brand new oncogenic interpretation program is an excellent therapeutic strategy when you look at the several myeloma. Sci Transl Med. 2017;9(389).
Magnez R, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X. PD-1/PD-L1 joining studies having fun with microscale thermophoresis. Sci Rep. 2017;7(1):17623.
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe Good, Dumezy F, Feuillard J, Genevieve F, Guerin Age, Son J, Jouault H, Lepelley P, Maynadie M, Solly F, Ballon OW, Preudhomme C, Baruchel An excellent, Dombret H, Ifrah N, Bene MC. Prognostic worth of multicenter flow cytometry matched up evaluation of minimal residual disease within the intense myeloblastic leukemia. Hematol Oncol. 2017.